Lyell
IPOUnited States · $834.0M raised
- Business Model
- B2B
- Total Funding
- $834.0M
- Last Round
- $493.0M Series CMar 2020
- Rounds
- 3
About
Clinical-stage cell therapy company developing next-generation CAR-T cell therapies for cancer patients.
Summary
Lyell is a Biotech company based in United States. It has raised $834.0M in total across 3 rounds, most recently a $493.0M Series C round in Mar 2020. Investors include ARCH Venture Partners, Foresite Capital and GSK.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Oct 2021
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...